Journal Article

Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C

Francesco G. De Rosa, Olivia Bargiacchi, Sabrina Audagnotto, Silvia Garazzino, Giuseppe Cariti, Riccardo Raiteri and Giovanni Di Perri

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 57, issue 2, pages 360-363
Published in print February 2006 | ISSN: 0305-7453
Published online January 2006 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dki458
Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C

Show Summary Details

Preview

Objectives: The optimal regimen for acute hepatitis C (AHC) is considered to be a 24 week treatment with interferon (IFN) alpha-2b. A 24 week treatment with pegylated IFN (PEG-IFN) alpha-2b is also effective. This study was designed to assess response rates to a 12 week regimen of PEG-IFN alpha-2b.

Patients and methods: Patients with AHC were treated with PEG-IFN alpha-2b for 12 weeks in an open, non-randomized, prospective cohort study. Diagnosis of AHC was made with positive serum HCV RNA and elevated alanine aminotransferase (ALT) levels with a documented seroconversion or a known risk factor in the preceding 6 months. Treatment was administered within a median of 31 days (range 0–116) of the ALT level peak at a dosage varying from 1.06 to 1.66 μg/kg/week. The primary end-point was a sustained virological response (SVR).

Results: Nineteen patients were treated, of whom 11 patients (57.9%) had HCV genotype 1. Fourteen patients were asymptomatic. An SVR was achieved in 74% of patients and the SVR rate was 100 and 83.3%, respectively, in genotype 1 and non-1 infected patients treated with a dosage ≥1.33 μg/kg, compared with 40 and 50%, respectively, in those who received a lower dosage. An SVR was significantly associated by multivariate analysis only with PEG-IFN dosage ≥1.33 μg/kg/week. No significant association was found with any viral genotype.

Conclusions: The rate of SVR was independent of the HCV genotype and was significantly associated by multivariate analysis only with the higher PEG-IFN dosage. Early identification and treatment of AHC is likely to decrease the burden of chronic hepatitis, especially when caused by HCV genotype 1.

Keywords: hepatitis C virus; acute hepatitis; interferon treatment; IFN; HCV

Journal Article.  2145 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.